Navigation Links
Transdel Pharmaceuticals Closes $4 Million Financing
Date:5/15/2008

Proceeds Will Support Phase 3 Lead Clinical Pain Program for

Ketotransdel(TM)

LA JOLLA, Calif., May 15 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP), a specialty pharmaceutical company focused on the development and commercialization of non-invasive topically administered medications, today announced the closing of a $4,000,000 private placement of its common stock and warrants.

The Company issued 1,818,180 shares of common stock at a price of $2.20 per share through a private placement to accredited investors. In addition, the investors received warrants to purchase 227,272 shares of common stock for a period of five years at a cash and cashless exercise price of $4.40 and $5.50 per share, respectively.

Proceeds from the financing will be primarily used to fund the Company's Phase 3 clinical program of Ketotransdel(TM), the Company's lead topical pain drug. Ketotransdel(TM) is a novel, topical cream-based formulation containing the non-steroidal anti-inflammatory drug ("NSAID") ketoprofen. The registration trial will be a randomized, double-blind, placebo controlled Phase 3 trial to study the efficacy and safety of Ketotransdel(TM) in acute soft tissue injuries.

Dr. Juliet Singh, President and Chief Executive Officer of Transdel Pharmaceuticals, stated, "We are very pleased to have closed this round of financing, as we plan to initiate our Phase 3 clinical study in the second quarter of this year. We are quite confident in our Phase 3 clinical study design, especially since our protocol was carefully reviewed by external experts and the U.S. Food and Drug Administration ("FDA"). We believe that Ketotransdel(TM) may address a significant unmet medical need for effective topical pain treatment without the gastrointestinal, cardiovascular and other safety concerns associated with oral pain medications."

The Company is exploring potential partnerships wit
'/>"/>

SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... disease, today announced the next step in its expanded ... solutions provider with the naming of current Chief Operating ... Executive Officer, while current Chairman of the Board and ... as Chairman. These changes are effective January 1, 2015. ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary commercial focus on ... has been granted a Type C meeting with the ... meeting will be held in February 2015.  During this ...
(Date:12/17/2014)... Mass. , Dec. 17, 2014   Synageva ... biopharmaceutical company developing therapeutic products for rare disorders, announced ... Conference being held in San Francisco, CA. ... President and Chief Executive Officer, will present on Monday, ... EST).  The presentation will be webcast live and may ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... FT. LAUDERDALE, Fla., July 30 OmniComm Systems, Inc. ... capture (EDC) solutions for clinical trials announced today that a ... provide eClinical solutions in connection with two of the CRO,s ... 700 subjects. Additional details were not disclosed. Phase IV studies ...
... , RALEIGH, N.C. , July 30 SmartGene, ... of genetic data, today announced that it has entered into an ... technology and integrated Web-based services to support more rapid and precise ... , Some bacteria and fungi do not grow quickly ...
... 30 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG) a biotechnology ... based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), ... with its vaccine candidate for the Influenza A (H1N1) ... a single dose of 5 micrograms induced a positive ...
Cached Biology Technology:Growing Midwestern Clinical Research Organization Selects OmniComm Systems to Provide eClinical Solutions for Phase IV Studies 2SmartGene's Services for Faster, More Precise Identification of Bacteria and Fungi to be Used by The Johns Hopkins Hospital 2Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose 2Medicago's H1N1 pandemic vaccine candidate shows positive response in 100% of vaccinated animals after a single dose 3
(Date:12/19/2014)... , Dec. 18, 2014  23andMe, Inc., the ... a study that pinpoints fine-scale differences in genetic ancestry ... . Since immigrants first arrived more ... States has served as a meeting place ... American history and the ongoing mixing of peoples with ...
(Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
(Date:12/17/2014)... , Dec. 16, 2014 Research and Markets ... addition of the "Global Chemical Sensor Market ... http://photos.prnewswire.com/prnh/20130307/600769 One ... increasing demand for medical sensors in biomedical applications. ... for quick and correct diagnosis during surgical procedures. ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... -- Look out, Indiana Jones. Dan Shain ... to frozen glaciers and the steamy Amazon planned, all ... cinematic icon, Shain, an associate professor of biology at ... returns home with treasure. He,s mined for ice ...
... Western Reserve University have developed a technique that has ... within hours, as opposed to the two days it ... mice, drug delivery time from injection to the cancer ... Using this as a model for potential human use, ...
... is a significant challenge for researchers. That challenge is prompting ... that data and to make it readily available. The ... Disease has created a new collaboration tool, WikiPathways to focus ... "Biological pathways connect genes and proteins in systems that ...
Cached Biology News:Rutgers biologist to study worms in Amazon, glaciers 2Cancer drug delivery research at Case Western Reserve University cuts time from days to hours 2Cancer drug delivery research at Case Western Reserve University cuts time from days to hours 3Gladstone scientists create Wikipathways to foster research collaboration 2
... This antibody is generated from rabbits immunized ... within aa 50~150 of human PLAU. Purified ... 0.09% (W/V) sodium azide. This antibody is ... eluted out with both high and low ...
... is a compact, lightweight, high current power supply ... 2500 milliamps. It is an excellent choice for ... It is also ideal for all types of ... set to automatically end a run and wil ...
... For use in Refrigerated Vapor Trap ... Vacuum Source (UVS) Models UVS400, UVS400A and ... polymer suitable for use for temperatures ranging ... has excellent thermal stability and does not ...
... proteomics demands the detection of very small ... the AXIMA-CFRplus with improved resolution (20,000) and ... increased confidence in protein identification. The AXIMA-CFRplus ... automated sample target handling and the ability ...
Biology Products: